Rivaroxaban product-specific bioequivalence guidance
Submitted by Anonymous (not verified) on 30 July 2025 - 9:59
Rivaroxaban product-specific bioequivalence guidance
Sitagliptin product-specific bioequivalence guidance
Submitted by Anonymous (not verified) on 30 July 2025 - 9:56
Sitagliptin product-specific bioequivalence guidance
Tacrolimus granules product-specific bioequivalence guidance
Submitted by Anonymous (not verified) on 30 July 2025 - 9:51
Tacrolimus granules product-specific bioequivalence guidance
Human medicines European public assessment report (EPAR): Xgeva, denosumab, Date of authorisation: 13/07/2011, Revision: 27, Status: Authorised
Submitted by Anonymous (not verified) on 29 July 2025 - 17:00
Human medicines European public assessment report (EPAR): Xgeva, denosumab, Date of authorisation: 13/07/2011, Revision: 27, Status: Authorised
PSUSA/00000375/202410
Submitted by Anonymous (not verified) on 29 July 2025 - 15:45
PSUSA/00000375/202410
PSUSA/00001911/202412
Submitted by Anonymous (not verified) on 29 July 2025 - 15:44
PSUSA/00001911/202412
Fingolimod product-specific bioequivalence guidance
Submitted by Anonymous (not verified) on 29 July 2025 - 15:43
Fingolimod product-specific bioequivalence guidance
Fingolimod capsules 0.25 and 0.5 mg product-specific bioequivalence guidance
Submitted by Anonymous (not verified) on 29 July 2025 - 15:43
Fingolimod capsules 0.25 and 0.5 mg product-specific bioequivalence guidance
Entecavir product-specific bioequivalence guidance
Submitted by Anonymous (not verified) on 29 July 2025 - 15:40
Entecavir product-specific bioequivalence guidance
Human medicines European public assessment report (EPAR): Eklira Genuair, aclidinium bromide, Date of authorisation: 20/07/2012, Revision: 22, Status: Authorised
Submitted by Anonymous (not verified) on 29 July 2025 - 15:22
Human medicines European public assessment report (EPAR): Eklira Genuair, aclidinium bromide, Date of authorisation: 20/07/2012, Revision: 22, Status: Authorised